Content
Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits.
One share of ZBH stock can currently be purchased for approximately $142.65. Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise. The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction. Get this delivered to your inbox, and more info about our products and services. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.
For example, the increasing popularity of non-surgical treatments for orthopedic conditions could affect the demand for joint replacement products. Zimmer Biomet’s stock performance has been mixed over the past few years. In early 2020, the company’s stock price experienced a sharp decline due to the COVID-19 pandemic, but since then, it has rebounded and continues to experience volatility. The company’s hip and knee replacement products continue to enjoy solid demand.
About Zimmer Biomet Holdings, Inc
Alternative Assets.Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured.
The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. 240 employees have rated Zimmer Biomet Chief Executive Officer Bryan Hanson on Glassdoor.com.
Recently Viewed Tickers
The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency1 basis Fourth quarter diluted loss per share from continuing operations was $0.62; …
Provides a general description of the business conducted by this company.
Start investing in Zimmer Biomet
First quarter net sales of $1.831 billion increased 10.1% and 13.2% on a constant currency1 basis First quarter diluted earnings per share were $1.11; adjusted1 diluted earnings per share were $1.89 C… According to 19 analysts, the average rating for ZBH stock is “Hold.” The 12-month stock price forecast is $137.64, which is a decrease of -3.51% from the latest price. Another risk facing Zimmer Biomet is the potential for increased competition. While the company is one of the most significant players in the orthopedic industry, it faces competition from other established companies and new entrants.
Hanson has over 30 years of experience in the medical device industry and has held various executive positions in leading medical device companies. Additionally, Zimmer Biomet’s executive team includes Chief Financial Officer Suketu Upadhyay and Chief Operating Officer Ivan Tornos. Zimmer Biomet Holdings Inc is a medical technology company that designs, develops and manufactures a wide range of orthopedic and musculoskeletal products. With headquarters in Warsaw, Indiana, the company was formed in 2015 after the merger of Zimmer Holdings and Biomet Inc, two of the world’s leading companies in the orthopedic industry. Zimmer Biomet’s mission is to help people alleviate pain, regain mobility and improve the quality of life for patients worldwide. Some of the biggest medical device companies’ stocks have dropped to attractive prices due to the current COVID-19 pandemic.
Recently Viewed
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Syneos Health’s (SYNH) share price movement is expected to be favorable due to the strength of the company’s Syneos https://g-markets.net/helpful-articles/46-psychological-marketing-examples-for-smarter/ One portfolio and several value-added partnership deals. Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business. Amid recessionary concerns, investing in medical stock Abbott Laboratories (ABT) could be wise given its sound financials and the…
- The Barchart Technical Opinion widget shows you today’s overally Barchart Opinion with general information on how to interpret the short and longer term signals.
- The company has a robust pipeline of new products in development, including the Persona Revision Knee System and the ROSA Knee System.
- As elective surgery candidates return to operating rooms, revenue will ramp up.
- Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency1 basis Fourth quarter diluted loss per share from continuing operations was $0.62; …
To maintain its market position, Zimmer Biomet must continue to innovate and invest in research and development. Zimmer Biomet is expanding its product portfolio through innovation and acquisitions. The company has a robust pipeline of new products in development, including the Persona Revision Knee System and the ROSA Knee System. Zimmer Biomet is also pursuing strategic acquisitions to expand its presence in emerging markets and strengthen its position in existing markets.
Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. The technique has proven to be very useful for finding positive surprises. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.
Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Shareholders of record on Monday, June 26th will be paid a dividend of $0.24 per share on Monday, July 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.67%. The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. Finally, changes in consumer preferences and healthcare trends could impact demand for Zimmer Biomet’s products.
Changes in regulatory requirements could increase the costs and time required to bring new products to market, affecting Zimmer Biomet’s ability to innovate and compete. In addition, insurance and hospital reimbursement policy changes could also impact the demand for Zimmer Biomet’s products. Over the past few years, Zimmer Biomet has reported steady financial performance. The company has reported increased revenue and profit margin for the past several years while also reporting a debt-to-equity ratio indicating a relatively low debt level. In 2021, the company also announced a share repurchase program of up to $1 billion, demonstrating its commitment to returning value to shareholders.
This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year.
